Printer Friendly

Camargo Adds VP Clinical Development & Chief Medical Officer, Samer E. Kaba, MD.

CINCINNATI -- First paragraph, first sentence should read: Camargo Pharmaceutical Services is pleased to announce the new Vice President of Clinical Development and Chief Medical Officer, Samer "Sam" Kaba, MD. (sted Chief Medial Officer).

The corrected release reads:

CAMARGO ADDS VP CLINICAL DEVELOPMENT & CHIEF MEDICAL OFFICER, SAMER E. KABA, MD

Camargo Pharmaceutical Services is pleased to announce the new Vice President of Clinical Development and Chief Medical Officer, Samer "Sam" Kaba, MD. Dr. Kaba will be responsible for the research services and clinical development at Camargo.

Dr. Kaba joins Camargo with over 20 years of combined clinical practice and clinical research, experience in academia, private practice and the pharmaceutical industry. He is a board certified neurologist with additional fellowship training in neuro-immunology and neuro-oncology. Dr. Kaba's extensive experience in protocol development and conducting clinical trials in a variety of therapeutic indications in Phases I-IV will be an asset to Camargo's clients.

"The addition of a Chief Medical Officer signals our strong dedication to having a team with enormous depth and breadth. We are quite excited to have Dr. Kaba join Camargo, his ability to apply medical expertise in a clinical research setting will provide our clients with additional support in developing their strategic programs," stated President and CEO, Ken Phelps. "Our expertise in 505(b)(2) drug development extends to the specialized designs of the clinical program. Dr. Kaba will enhance our ability to deliver efficient clinical trials to our clients."

Most recently, Dr. Kaba was the vice president of global medical affairs and strategic product development at Premier Research Group, LLC, in Philadelphia, PA. He managed a team of physicians across the globe and served on the Premier Research senior executive committee. In addition, Dr. Kaba provided input on the strategic and tactical aspects of clinical trials (study design, selection of countries, selection of investigative sites, designing and conducting feasibility studies, etc.) and facilitated communication with key opinion leaders and principal investigators.

Dr. Kaba also brings leadership experience to Camargo from his roles as vice president of clinical research and medical management at SCIREX Corporation in Horsham, PA, and senior director of global product development services, PRA International in McLean, VA. Prior to joining the pharmaceutical industry, Dr. Kaba served as director of research, MS Center at Shepherd in Atlanta, GA, and associate professor of neurology at the University of Arkansas for Medical Sciences. He continues to hold an adjunct faculty position at the department of neurology at Emory University in Atlanta. Dr. Kaba obtained his medical degree from Damascus University School of Medicine in Damascus, Syria. He completed his neurology training and a fellowship in neuro-immunology at the State University of New York at Buffalo, and fellowship training in neuro-oncology at the University of Texas MD Anderson Cancer Center in Houston. He has multiple scientific publications and book chapters in the fields of neurology and neuro-oncology.

About Camargo Pharmaceutical Services

Camargo Pharmaceutical Services is a full-service CRO for the continuum of drug development. With more than 150 FDA approvals, Camargo works with companies to develop comprehensive programs, managing every facet of the plan from formulation and testing the drug product, conducting clinical studies and FDA application submissions. Visit www.camargopharma.com for more information.
COPYRIGHT 2009 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 3, 2009
Words:535
Previous Article:Universal American Corp. Schedules Fourth Quarter Financial Results Release for Tuesday, February 17th and Conference Call for Wednesday, February...
Next Article:New York City Comptroller William C. Thompson, Jr. to Headline DC Finance's Annual Israeli Institutional Investor Conference 2009.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters